Phathom Pharmaceuticals, Inc. (PHAT) Stock

Phathom Pharmaceuticals, Inc. (PHAT) is a Healthcare stock trading at $10.89 (as of 2026-06-18), with a market capitalization of $764.86M and a trailing P/E of -4.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on gastrointestinal disease treatments. It has rights in the United States, Europe, and Canada to vonoprazan and is developing it for erosive gastroesophageal reflux disease and in combination with antibiotics for Helicobacter pylori infection.

Valuation — source: SEC EDGAR (first-party)
Price	$10.89
Market Cap	$764.86M
P/E Ratio	-4.6
EV / EBITDA	-7.8
Price / Book	-2.27
Price / Sales	3.73
DCF Value (model)	$-37.08
DCF Upside vs Price	-440.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$175.11M
Net Margin	-126.3%
Return on Equity	46.7%
Debt / Equity	-0.49
Current Ratio	2.21
Revenue Growth (YoY)	216.9%
EPS Growth (YoY)	-42.7%
FCF Growth (YoY)	-37.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-8.19 (distress)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-4.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-121.9%
vs Industry	-126.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Frazier Life Sciences Management, L.P. ($138.50M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Steven L. Basta
Employees	427
Country	US
IPO Date	2019-10-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.